A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortez
A phase 3 trial of Talquetamab, Pomalidomide, Teclistamab in multiple myeloma, run by Janssen Research & Development, LLC, active and no longer recruiting.
Overview
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide is a phase 3 interventional study registered as NCT06208150 by Janssen Research & Development, LLC, with 838 participants enrolled, started 2024-01-22 and due to reach its primary completion in 2026-04-01. Interventions recorded: Talquetamab, Pomalidomide, Teclistamab, Elotuzumab, Dexamethasone. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With
Shares Teclistamab, Pomalidomide, Bortezomib, Dexamethasone.
- TrialA Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination Wi
Shares Talquetamab, Pomalidomide, Dexamethasone, Johnson & Johnson.
- TrialA Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal
Shares Talquetamab, Teclistamab, Dexamethasone, Johnson & Johnson.
- TrialA Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Shares Talquetamab, Teclistamab, Johnson & Johnson, Multiple myeloma.
- TrialMagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other
Shares Elotuzumab, Pomalidomide, Bortezomib, Dexamethasone.
- TrialStudy Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refracto
Shares Elotuzumab, Pomalidomide, Bortezomib, Dexamethasone.
- TrialA Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Ind
Shares Talquetamab, Teclistamab, Bortezomib, Johnson & Johnson.
- TrialA Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Re
Shares Elotuzumab, Pomalidomide, Dexamethasone, Multiple myeloma.